Evidence map›Paper›PMID 25432067›Full record

ReviewToxicon : official journal of the International Society on Toxinology2015

Scorpion venom components as potential candidates for drug development.

Ernesto Ortiz, Georgina B Gurrola, Elisabeth Ferroni Schwartz, Lourival D Possani

Abstract readReview
In one paragraph

Review in Toxicon : official journal of the International Society on Toxinology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 154 papers.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

154 citing papers in PubMed.

  1. Article
  2. Article
  3. Scorpion Peptides in Antiviral Drug Discovery: An In-depth Review.Probiotics and antimicrobial proteins · 2026
    Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ernesto OrtizDepartamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autonóma de México, Avenida Universidad 2001, Cuernavaca 62210, Mexico.
Georgina B GurrolaDepartamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autonóma de México, Avenida Universidad 2001, Cuernavaca 62210, Mexico.
Elisabeth Ferroni SchwartzDepartamento de Ciências Fisiológicas, Instituto de Ciências Biológicas, Universidade de Brasília, Brasília 70910-900, DF, Brazil.
Lourival D PossaniDepartamento de Medicina Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autonóma de México, Avenida Universidad 2001, Cuernavaca 62210, Mexico. Electronic address: possani@ibt.unam.mx.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scorpions are well known for their dangerous stings that can result in severe consequences for human beings, including death. Neurotoxins present in their venoms are responsible for their toxicity. Due to their medical relevance, toxins have been the driving force in the scorpion natural compounds research field. On the other hand, for thousands of years, scorpions and their venoms have been applied in traditional medicine, mainly in Asia and Africa. With the remarkable growth in the number of characterized scorpion venom components, several drug candidates have been found with the potential to tackle many of the emerging global medical threats. Scorpions have become a valuable source of biologically active molecules, from novel antibiotics to potential anticancer therapeutics. Other venom components have drawn attention as useful scaffolds for the development of drugs. This review summarizes the most promising candidates for drug development that have been isolated from scorpion venoms.

Indexed as

Angiotensin-Converting Enzyme InhibitorsAnti-Infective AgentsAntimicrobial Cationic PeptidesAntineoplastic AgentsBiological ProductsDrug DiscoveryHumansImmunologic FactorsPotassium Channel BlockersScorpion VenomsAngiotensin-Converting Enzyme InhibitorsAnti-Infective AgentsAntimicrobial Cationic PeptidesAntineoplastic AgentsBiological ProductsImmunologic FactorsPotassium Channel BlockersScorpion VenomsAnticancer peptidesAntimicrobialsBradykinin-potentiating peptidesDrug candidatesImmune-modulatorsScorpion venom

Identifiers

PMID25432067
PMCPMC7130864

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.